Volta Labs announced on November 12, 2026, that it has introduced an automated AXELIOS 1 Library Prep App for its Callisto Sample Prep System in collaboration with Roche Diagnostics. The application automates preparation of purified genomic DNA for Roche’s AXELIOS 1 sequencing platform using SBX-D chemistry, supporting whole-genome sequencing research with a workflow that handles between four and 24 samples per run.
The launch addresses a practical constraint in next-generation sequencing laboratories: the preparation of sequencing-ready DNA libraries can require substantial manual intervention even when sequencing instruments are highly automated. Volta Labs says its new application reduces hands-on library preparation to approximately one hour, compared with around ten hours for the referenced manual workflow. The system performs a roughly 16-hour automated run, enabling laboratories to prepare libraries overnight for sequencing the following day.
The application has been rolled out and is undergoing testing across Volta Labs’ installed customer base, while the company is demonstrating Callisto at the Association for Molecular Pathology 2026 Annual Meeting in Seattle. The launch does not represent a new clinical diagnostic authorisation, and Callisto remains designated for research use only. Its commercial significance will depend on whether laboratories can reproduce the reported performance under routine operating conditions and justify the associated instrument, consumable and workflow costs.
Why is automated library preparation important for AXELIOS 1 whole-genome sequencing?
Whole-genome sequencing requires DNA molecules to be processed into libraries compatible with the chemistry and architecture of the selected sequencing platform. Depending on the technology, preparation can involve fragmentation, end repair, adapter ligation, amplification and purification. These stages influence library quality and can contribute substantially to laboratory workload.
Manual library preparation creates multiple opportunities for variation between operators, experiments and laboratory environments. Technicians must perform repeated transfers, measure reagents, observe incubation times and monitor reaction conditions. Errors or inconsistencies can affect DNA recovery, fragment distributions and downstream sequencing quality.
Automation is intended to control these steps more consistently while reducing operator involvement. A workflow that performs multiple processes within one instrument may also reduce the need for separate equipment, repeated sample transfers and manual scheduling. These potential benefits become particularly relevant when laboratories increase sequencing volumes or introduce additional sequencing platforms.
Volta Labs’ new application is designed specifically for Roche’s SBX-D library preparation chemistry. It begins with 50 nanograms of purified genomic DNA and converts that input into sequencing-ready libraries for AXELIOS 1. The application is intended for whole-genome research, including germline sequencing studies, rather than providing an independently validated diagnostic testing procedure.
The compatibility is strategically relevant because Roche launched AXELIOS 1 globally in June 2026 as a next-generation sequencing platform based on sequencing by expansion technology. Introducing automation for library preparation creates a more complete research workflow around that sequencing system. However, automated preparation must be evaluated separately from the performance of the sequencer itself.
How does the Callisto AXELIOS 1 app reduce laboratory hands-on time?
Volta Labs reports that the AXELIOS 1 application requires approximately 45 minutes for initial setup and a further 15-minute intervention during processing. The remainder of the workflow is automated, with a total instrument run time of approximately 16 hours. This allows a laboratory to begin preparation during one working day and retrieve sequencing-ready libraries the following morning.
The application incorporates several library preparation processes, including DNA fragmentation, end processing, size selection, adapter ligation, amplification and purification. One mid-run interaction is required to add an amplification initiator before the automated sequence continues. The workflow is therefore substantially automated, although it is not completely unattended from beginning to end.
Volta Labs’ published workflow comparison indicates that manual preparation requires around ten hours and twenty minutes of hands-on work, compared with approximately one hour using Callisto. This represents a reduction of more than nine hours in operator time under the described conditions. The saving should not be confused with a corresponding reduction in total elapsed processing time because the automated run continues for approximately sixteen hours.
The distinction matters for laboratories evaluating productivity. Automation may allow trained staff to perform other activities while the instrument completes processing, even if the overall procedure is not dramatically shorter. Staff availability, scheduling flexibility and reduced manual intervention can influence operational capacity independently of the time required to complete an individual run.
The application supports batches ranging from four to 24 samples. This flexibility may be valuable for laboratories handling variable research demand, since smaller batches can be processed without waiting to accumulate the maximum number of samples. Nevertheless, the economics of a smaller batch will depend on consumable utilisation and how the laboratory’s operating costs are structured.
Existing Callisto customers can add the compatible application without purchasing a new sample preparation instrument, according to Volta Labs. This reduces one potential barrier to adoption for its installed base, although compatible reagents, application setup, training and workflow qualification remain relevant. Laboratories without Callisto would still need to evaluate the capital expenditure associated with purchasing the system.
What do Volta Labs’ sequencing quality benchmarks reveal about automated preparation?
Volta Labs has published preliminary application performance information comparing automatically prepared libraries with manually prepared material. In a library yield assessment using Genome in a Bottle reference material HG001, the company reported a median yield of 5.46 picomoles across 64 Callisto-prepared libraries, compared with 4.78 picomoles across twelve manually prepared libraries. These measurements indicate successful library production under the evaluated conditions.
A higher measured library yield does not automatically mean a better clinical or analytical outcome. Sequencing performance depends on factors such as library complexity, fragment characteristics, coverage distribution, read quality and downstream analysis. The difference between the reported median yields also should not be interpreted as statistically significant without an appropriate comparative analysis.
The company additionally reported germline variant calling benchmarks using AXELIOS 1 and the Genome in a Bottle high-confidence reference set. Across the disclosed validation data, automated preparation produced a median single nucleotide polymorphism F1 score of 99.38%, compared with 99.45% for manually prepared libraries. The corresponding insertion and deletion F1 scores were 99.38% and 99.54%.
F1 score combines precision and recall into a measure of variant calling performance. These results indicate that automated library preparation produced highly concordant variant calls in the evaluated reference dataset, but they do not establish equivalent performance across every sample type or sequencing application. Differences in genomic context, DNA quality and analysis pipelines can influence observed accuracy.
The benchmark used a well-characterised reference sample, making it useful for assessing technical performance under defined conditions. However, routine research laboratories may process samples with substantially different characteristics, including degraded DNA, difficult genomic regions or varying extraction quality. Broader testing will be necessary to understand the extent to which the reported performance generalises across intended research workflows.
Volta Labs’ performance claims therefore provide encouraging technical evidence but should not be interpreted as proof of clinical diagnostic accuracy. The application and underlying platform are intended for research use, and the published benchmark does not establish that they improve patient outcomes or meet the requirements of a clinical diagnostic procedure.
How does Roche’s sequencing by expansion technology influence library preparation requirements?
Roche’s AXELIOS 1 platform uses sequencing by expansion technology, which separates aspects of molecular information generation from subsequent electronic detection. The platform converts sequencing information into expanded molecular structures known as Xpandomers before measurement. This architecture differs from conventional sequencing approaches that couple nucleotide incorporation and signal detection through repeated cycles.
The technology is designed to support high-throughput genomic research, including whole-genome sequencing. Roche has described AXELIOS 1 as capable of generating at least 1.8 terabases of concordant duplex sequence output during a four-hour sequencing run under specified conditions. The company estimates that this can support approximately sixteen human genomes at a defined 30-fold coverage level.
Those figures relate to sequencing performance rather than the end-to-end time required to prepare DNA, complete all upstream processes and analyse results. Library preparation remains a separate stage that must produce compatible material with suitable concentration and quality. The Volta Labs application addresses this upstream requirement.
The collaboration therefore connects two specialised elements of the sequencing workflow. Roche provides the sequencing platform and associated chemistry, while Volta Labs supplies automation for a compatible library preparation process. This arrangement may help laboratories integrate AXELIOS 1 into existing operations, particularly where sample preparation is a significant source of manual workload.
Compatibility with new sequencing architectures can also affect how laboratories select automation equipment. A system capable of supporting multiple sequencing chemistries may offer greater operational flexibility than equipment restricted to a single library preparation protocol. However, performance and reagent compatibility must be established for each application independently.
Volta Labs has indicated that the AXELIOS 1 application is the first of several planned workflows for the Roche platform. Those future applications could expand the range of supported research processes, but the November announcement establishes only the availability and ongoing testing of the current SBX-D library preparation application.
Could Callisto automation change genomics laboratory purchasing decisions?
Genomics laboratories face investment decisions that extend beyond the purchase of a sequencing instrument. They must consider sample preparation equipment, reagent costs, staffing requirements, throughput, maintenance, data processing and quality control. An automated library preparation workflow could influence several of these factors.
For existing Callisto customers, software and application compatibility may reduce the need for additional hardware as laboratories introduce AXELIOS 1. This could support the value of a multipurpose sample preparation platform, particularly for organisations operating several sequencing technologies. However, the incremental cost of application-specific kits and reagents remains an important consideration.
For laboratories evaluating new equipment, the commercial case is more complicated. An automated system may reduce operator time but introduce capital expenditure, maintenance obligations and consumable costs. The appropriate comparison is therefore not simply manual processing hours versus automated processing hours, but the total cost per usable sequencing-ready library at the laboratory’s expected workload.
Reagent utilisation and batch flexibility can materially influence that calculation. A laboratory regularly processing 24 samples may achieve different economics from one handling only four samples at a time. Reliability, failed-run frequency and the ability to repeat assays can also have a significant effect on operating costs.
Supplier relationships add another dimension. By collaborating with Roche Diagnostics, Volta Labs can position Callisto within an expanding sequencing technology ecosystem. However, the announcement does not disclose a guaranteed revenue commitment, minimum purchase volume or financial terms associated with the collaboration.
The new application may support recurring consumable demand as customers process samples, but actual revenue depends on adoption and utilisation. The commercial opportunity should therefore be understood as a potential extension of Volta Labs’ installed-base business rather than an immediately quantified financial contribution.
What must laboratories validate before adopting the automated AXELIOS 1 workflow?
Laboratories considering the application will need to assess whether its analytical performance is suitable for their intended research protocols. Relevant measures include library yield, fragment distribution, coverage uniformity, variant calling concordance, sample recovery and repeatability. Performance should also be assessed using sample materials representative of the laboratory’s actual workload.
Workflow implementation will require appropriate staff training and operating procedures. Although the application is pre-optimised, laboratories remain responsible for confirming that their equipment, reagents and quality systems produce acceptable results. A reduction in manual steps does not remove the need for documentation, instrument maintenance or investigation of unexpected findings.
Integration with downstream sequencing operations is another practical requirement. Prepared libraries must be transferred to the compatible AXELIOS 1 workflow, and laboratories need appropriate tracking systems to preserve sample identity and data integrity. Automation can reduce some manual handling risks, but successful deployment depends on reliable coordination between preparation, sequencing and bioinformatics processes.
The research-use-only restriction is particularly important where genomic technologies are associated with clinical applications. Volta Labs’ announcement does not authorise Callisto for diagnostic procedures or establish clinical performance across patient populations. Any future diagnostic application would require appropriate evidence and regulatory consideration for its intended use.
The launch gives Volta Labs a credible new compatibility offering within the expanding next-generation sequencing market. Its reported hands-on time reduction and initial variant calling benchmarks establish useful technical starting points, but routine laboratory performance remains the decisive test. Commercial adoption will depend on whether Callisto can consistently deliver acceptable sequencing libraries while improving staff utilisation and total workflow economics.
